ERBB2 and breast cancer: As shown in Supplementary Figures S4A–C, an increase in SGPP1 promoter methylation status was noted in patients with TNBC; however, no significant difference in the methylation status of the SGPP1 promoter was observed in the other BC subtypes (luminal and HER2+) vs. normal subjects.